{"id":"NCT03525119","sponsor":"Takeda","briefTitle":"Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine","officialTitle":"A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) Vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Country(Ies) for Dengue","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-16","primaryCompletion":"2018-10-03","completion":"2019-07-09","firstPosted":"2018-05-15","resultsPosted":"2020-07-13","lastUpdate":"2022-08-19"},"enrollment":900,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Healthy Volunteers"],"interventions":[{"type":"BIOLOGICAL","name":"TDV","otherNames":[]},{"type":"BIOLOGICAL","name":"HAV Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"TDV Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"HAV Vaccine Placebo","otherNames":[]}],"arms":[{"label":"HAV Vaccine 1.0 ml + Placebo/ Placebo","type":"OTHER"},{"label":"TDV 0.5 ml + Placebo/ TDV 0.5 ml","type":"EXPERIMENTAL"},{"label":"TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the immunogenicity and safety of the concomitant administration of TDV (subcutaneous \\[SC\\] injection) and of hepatitis A virus (HAV) vaccine (intramuscular \\[IM\\] injection) in healthy participants aged 18 to 60 years living in country(ies) non-endemic for both dengue and hepatitis.","primaryOutcome":{"measure":"Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30","timeFrame":"One month post first vaccination (Day 30)","effectByArm":[{"arm":"HAV Vaccine 1.0 ml + Placebo/ Placebo","deltaMin":97.1,"sd":null},{"arm":"TDV 0.5 ml + Placebo/ TDV 0.5 ml","deltaMin":9.1,"sd":null},{"arm":"TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml","deltaMin":98.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["United Kingdom"]},"refs":{"pmids":["36681529"],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b60224db2bf003ab4969e?idFilter=%5B%22DEN-314%22%5D"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":299},"commonTop":["Nasopharyngitis"]}}